Blurbs

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and Akebia Therapeutics (AKBA)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Roche Holding AG (RHHVFResearch Report) and Akebia Therapeutics (AKBAResearch Report).

Roche Holding AG (RHHVF)

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on Roche Holding AG, with a price target of CHF425.00. The company’s shares closed last Wednesday at $389.20.

According to TipRanks.com, Papadakis is a 3-star analyst with an average return of 3.3% and a 56.4% success rate. Papadakis covers the Healthcare sector, focusing on stocks such as Novo Nordisk, Moderna, and Sanofi.

Currently, the analyst consensus on Roche Holding AG is a Moderate Buy with an average price target of $435.00, representing a 10.4% upside. In a report released yesterday, Bernstein also maintained a Buy rating on the stock with a CHF430.00 price target.

See the top stocks recommended by analysts >>

Akebia Therapeutics (AKBA)

H.C. Wainwright analyst Ed Arce downgraded Akebia Therapeutics to Hold today and set a price target of $2.00. The company’s shares closed last Wednesday at $0.83, close to its 52-week low of $0.67.

According to TipRanks.com, Arce is a 4-star analyst with an average return of 13.2% and a 41.1% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Madrigal Pharmaceuticals, and Aurinia Pharmaceuticals.

Currently, the analyst consensus on Akebia Therapeutics is a Hold with an average price target of $3.80, implying a 62.7% upside from current levels. In a report released yesterday, Piper Sandler also downgraded the stock to Hold with a $2.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on RHHVF:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos